The high effect of chemomobilization with high-dose etoposide + granulocyte-colony stimulating factor in autologous hematopoietic peripheral blood stem cell transplantation: a single center experience

Şebnem Izmir Güner,1 Mustafa Teoman Yannaz,2 Ahmet Selvi,3 Cigdem Usul4 Departments of 1Hematology, 2Medical Oncology, 3Pulmonary Medicine, Istanbul Kemerburgaz University, Medical Park Bahcelievler Hospital, Istanbul; 4Department of Medical Oncology, Istanbul Research and Education Hospital, Istanbul, Turkey

Abstract

Autologous hematopoietic stem cell transplantation (auto-HSCT) provides hematopoietic support after high-dose chemotherapy and is the standard of care for patients with multiple myeloma (MM), chemo sensitive relapsed high or intermediate grade non-Hodgkin’s lymphoma (NHL) and Hodgkin’s lymphoma (HL). However, yields of hematopoietic stem cells vary greatly between patients, and the optimal strategy to mobilize hematopoietic stem cells into peripheral blood for collection has not been defined yet. We investigated the efficacy and safety of chemo mobilization with an intermediate dose etoposide (VP-16; 200 mg/m² on days 1-3) and granulocyte-colony stimulating factor (G-CSF) (5 μg/kg twice daily from day 4 through the final day of collection). We reviewed our institutional experience with 91 patients (71 MM, 12 HL, 8 NHL) mobilized with this regimen. VP-16 + G-CSF resulted in successful mobilization in 95.55% of the patients (on one patient stem cell collection with plerixafor was applied), including 76 patients (83.52%) whose stem cells were collected successfully in a single day. Collection was managed between min. D8 and max. D17. Patient age, gender, exposure to previous irradiation and chemotherapy, previous mobilization attempts, and disease characteristics were not considered during selection. Adverse effects of the regimen included supportive transfusions and fevers requiring hospitalization or intravenous antibiotics. VP-16 and G-CSF appears to be a safe and effective mobilization regimen for patients with multiple myeloma, non-Hodgkin’s lymphoma and Hodgkin’s lymphoma undergoing autologous stem cell transplantation, producing excellent stem cell yield with the majority of patients requiring 1 day of apheresis.

Introduction

Autologous hematopoietic SCT (auto-HSCT) is the standard of care for patients with multiple myeloma (MM) or chemosensitive relapsed higher and intermediate grade non-Hodgkin’s lymphoma (NHL) and Hodgkin’s lymphoma (HL). It also provides essential hematopoietic support after the administration of high-dose therapy (HDT).1,2 Although MM is an incurable malignancy, auto-HSCT used in conjunction with HDT has shown to prolong survival.3-5 The rates of complete response to conventional therapy without auto-HSCT in patients with MM are between 5-15%.4,6 Auto-HSCT in combination with HDT can increase the rates of complete response to 20-44% and is associated with a very low incidence of treatment related mortality.1,6 Auto-HSCT combined with HDT administration after relapse, has shown to prolong the duration of remission in patients with diffuse large B-cell lymphoma and provides these patients with approximately a 45% probability of long-term disease free survival.6 Auto-HSCT is also used in conjunction with high-dose myeloablative therapy as a salvage treatment for follicular lymphoma. Although controversial, recent data suggest that more than 10-year disease free survival is possible after salvage auto-HSCT for patients with follicular lymphoma and Hodgkin’s lymphoma.7 In addition, auto-HSCT may improve the prognosis in patients with mantle cell lymphoma, specifically when it is used as part of first-line treatment.

The success of auto-HSCT is influenced by a number of factors. The most important one is the dose of reinfused stem cells. Higher stem cell doses are associated with faster platelet (PLT) engraftment (generally defined as PLT count >20x10⁹/L), faster neutrophil (ANC) engraftment (generally defined as ANC >0.5x10⁹/L)8-12 and reduction in the need for supportive measures such as transfusions of packed red blood cells (RBCs) and PLT and administration of prophylactic antibiotics.7,11 In some studies, higher stem cell doses have been associated with higher rates of survival for patients.14,15 Other factors that affect collection efficiency and the success of auto-HSCT include patient age, gender, exposure to previous irradiation and chemotherapy, previous mobilization attempts, and disease characteristics such as the involvement of bone marrow (BM).13,16 Unsuccessful initial stem cell mobilization leads to costly additional mobilization attempts and even may prohibit auto-HSCT.6,14-16 Current regimens to mobilize PBSC for auto-HSCT have differing stem cell yields, safety considerations, resource utilization, and levels of contamination of the apheresis product with tumor cells.2,10 The two most common mobilization strategies are using cytokines alone or cytokines after chemotherapy.

Mobilization using Food and Drugs Administration approved cytokines alone is generally well tolerated; however, yields are often suboptimal and collection of sufficient numbers of stem cells to support transplantation can be difficult, particularly in patients who have previously been treated with multiple rounds of intensive chemotherapy.14 The efficiency of granulocyte-colony stimulating factor (G-CSF) alone in certain patient groups is quite good, although there have been several different patient populations identified as difficult to mobilize. Failure rates of G-CSF alone have been variably reported between 1% and 40%.17 Recently, in large phase 3 studies, only 34% of patients mobilized with only G-CSF are able to collect 6x10⁹ CD34+ cells/kg in 2 days of apheresis.18 In contrast, mobilization with chemotherapy in addition to cytokine has been previously demonstrated to increase stem cell yields at the time of collection.16 Most of this data has been reported with the use of cyclophosphamide (Cy) in addition to G-CSF, in which stem cell yields and failure rates have been improved in comparison to G-CSF alone.

The addition of a myelosuppressive chemotherapeutic agent to a cytokine mobi-
lization regimen improves collections by a factor of 2.5 and can reduce the number of apheresis sessions needed for cell collection.18,19

Potential disadvantages of adding chemotherapy to mobilization include increased complications such as cytopenias requiring transfusion support, febrile neutropenia requiring hospitalization, and intravenous antibiotics. Further disadvantages are inability to schedule patients for apheresis due to difficulty in predicting peak PB CD34+ cell recovery, unpredictability regarding the optimal day for stem cell collection and delayed engraftment.3,9,10,15

Conversely, other studies have demonstrated comparable ANC and PLT engraftment kinetics for patients mobilized with either chemotherapy in combination with cytokines or cytokines alone.3,8-10,14 Although growth factor mobilization is associated with lower cell yields when compared to chemomobilization,3,8,10,15 it is also associated with lower toxicity and more predictable mobilization, thereby permitting easy apheresis scheduling.

There is available data that support the ability of high-dose etoposide (VP-16) to effectively mobilize progenitor cells.9 There is also one data about the routine addition of VP-16 to G-CSF in the mobilization of patients with MM.10

This study was aimed to use an intermediate dose of etoposide (200 mg/m² per day for 3 days) to preserve progenitor cell mobilization and antitumor properties while limiting other potential toxicities including myelodyplasia, mucositis, hepatic dysfunction, or prolonged cytopenias associated with higher doses of this or other agents. With this institutional experience we are reporting the safety and efficacy of this regimen.

Materials and Methods

Patients and treatment

This study was conducted on 91 patients between the ages of 20 and 67 years who received mobilization with VP-16 and G-CSF prior to ASCT for MM, NHL, and HL at our institution between the years 2010 and 2014. The mobilization regimen consisted of placement of a central apheresis catheter (Hickman hemodialysis/apheresis long term central venous catheter) followed by administration of intravenous VP-16 (200 mg/m²) once daily on D1-3. Each VP-16 infusion was diluted to a concentration of 0.5 mg/mL and infused over 4 hours. G-CSF was administered at a dose of 5 µg/kg twice daily starting on D 4 and continuing through the last day of stem cell collection. Antimicrobial prophylaxis was not given.

Complete blood counts were determined daily. Monitoring of peripheral blood CD34+ cell counts, was started when the WBC count in the blood exceeds 1.0 to 5.0 x 10⁹/L. Apheresis was performed daily using continuous flow blood cell separators, Fenwal CS3000 Plus (Fenwal, Deerfield, IL, USA). Peripheral blood CD34+ cell counts were checked routine-

ly, except for the patients who to have normal or high total white blood cell counts. Apheresis was initiated when the peripheral blood CD34+ cell count was >20 µ/L1,14 and all patients had stem cells collected between days 8 and 17 (median day 11.31, after D1 of chemotherapy). CD34+ determination was conducted in daily leukapheresis samples before cryopreservation with 10% dimethylsulfoxide by controlled-rate freezing. Cells were stored at −196°C until thawing for transplantation.

Target volumes were calculated based on an algorithm that includes the patient’s weight in kilograms, the peripheral precollection CD34+ count, and the requested cell dose (usually a minimum of 2.39 x 10⁶ CD34+ cells/kg and a maximum of 84.93 x 10⁶ CD34+ cells/kg) (medi-

an 33.73 x 10⁶ CD34+ cells/kg). The main goal of the collection was to obtain more than 2.0 x 10⁹/kg patient body weight of CD34+ cells. CD34+ cells were determined according to the International Society of Hematotherapy and Graft Engineering Guidelines as previously described. All collections were done using the Fresenius kabi Com.tec.continuous flow separa-
tor cell equipment (Fresenius kabi, Bad Homburg, Germany).

Platelet transfusions were administered routinely for platelet counts <10.000 x 10⁹/L, with higher thresholds used for patients at a higher risk for clinically significant bleeding. ASCT was performed using melphalan (200 mg/m², reduced to 140 mg/m² for patients with comorbid illness) for MM patients or BEAM chemotherapy protocol for HL and NHL patients followed by stem cell infusion.

Results

Between years 2010 and 2014, a total of 91 patients with MM, NHL and HL underwent stem cell mobilization. Collection with VP-16 and G-CSF were followed by ASCT in 91 patients (10 prior to ASCT for patients with this regimen, 37 patients (40.66%) received 2 regi-

mens, 3 patients (3.3%) received 3 regimens, and 3 patients (3.3%) received 4 prior regi-

mens.

The NHL and HL diagnosed patients were all in remission; MM diagnosed patients were 30 (42.25 %) in remission and 41 (57.75%) in very good response condition (VGPR-Very Good Partial Remission) before collecting their stem cell. Median bone marrow (BM) cellularity prior to mobilization for patients with this information available on chart review was 55% (range: 60-95%), with a median 5% plasma cell involvement (range: 1-10%) in MM patients; the other patients (HL and NHL patients) haven’t any bone marrow disease involvement (Table 1).

On 76 patients (83.52%) stem cells were successfully collected after 1 day of aphere-
sis,13 patients (14.29%) required 2 days of collec-
tion, 2 patients (2.2%) required 3 days of collection. Patients collected on min. day 8, with the max. Day 17 (median day 11.31).

The median peak peripheral blood CD34+ cell count during the collection period was 193.7/µL and the median collected CD34+ cell number was 33.73 x 10⁹ cells/kg (range: 2.39 x 10⁶ - 84.93 x 10⁹). Viabilite median range was 15.14 x 10⁶ cells/kg (range: 2.01 x 10⁶ - 83.76 x 10⁹). The patient with poor mobilized has a CD34+ cell of 2.39 x 10⁶ cells/kg.

The median time to neutrophil engraftment was 11.3 days (min. 6 days, max. 23 days), and the median time to a platelet count >20,000 for more than 7 days without transfusion were 13.92 days (min. 7 days, max. 30 days). There was one patient who was defined as poor engrafters, engrafing beyond one standard deviation, which was more than 23 days for neutrophils and 30 days for platelets (Table 2).

Antibacterial therapy was given about medi-
an 21 days after a febrile neutropenic attack. The patient’s hospitalization time was medi-
an 32.48 days (min. 19 days, max. 63 days).

Because of the high efficacy of this mobi-
lization regimen and thus the very small num-
ber of poor mobilizers, none of the following variables were associated with poor mobiliza-
tion in this patient population: age, receipt of prior radiation therapy, duration of prior chemotherapy, BM cellularity and disease involvement at the time of mobilization, peripheral white blood cell count and platelet count at the time of mobilization.

Survival and relapse information

Out of the total of 91 patients that had been followed for survival information, 8 have died and 83 were still alive at the time of analysis. The median follow-up time for survivors was 48 months. Ten patients have either relapsed (2 MM patients received lenalidomide treat-
Table 1. Patients' characteristics.

<table>
<thead>
<tr>
<th>Variable</th>
<th>Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>Variable</td>
<td>Number</td>
</tr>
<tr>
<td>Total</td>
<td>91</td>
</tr>
<tr>
<td>Median age, range</td>
<td>52.61  (28-67)</td>
</tr>
<tr>
<td>Male sex, %</td>
<td>60     (65.94)</td>
</tr>
<tr>
<td>Female sex, %</td>
<td>31     (34.06)</td>
</tr>
<tr>
<td>Number of prior treatment regimens, %</td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>48     (52.75)</td>
</tr>
<tr>
<td>2</td>
<td>37     (40.66)</td>
</tr>
<tr>
<td>3</td>
<td>3      (3.3)</td>
</tr>
<tr>
<td>4</td>
<td>3      (3.3)</td>
</tr>
<tr>
<td>Prior radiation therapy, %</td>
<td>24     (26.37)</td>
</tr>
<tr>
<td>Marrow cellularity percentage prior to mobilization (range)</td>
<td>55     (60-95)</td>
</tr>
<tr>
<td>Marrow disease involvement at mobilization (range), %</td>
<td>5      (0-10)</td>
</tr>
</tbody>
</table>

Table 2. Mobilization efficacy.

<table>
<thead>
<tr>
<th>Criteria</th>
<th>Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>Successful collection after 1 mobilization, %</td>
<td>76     (83.52)</td>
</tr>
<tr>
<td>Patients collecting &gt;10×10⁶ CD34⁺ cells/kg</td>
<td>48     (43.68)</td>
</tr>
<tr>
<td>Patients collecting &gt;5-10×10⁶ CD34⁺ cells/kg</td>
<td>28     (30.76)</td>
</tr>
<tr>
<td>Patients collecting &lt;4×10⁶ CD34⁺ cells/kg</td>
<td>15     (25.56)</td>
</tr>
<tr>
<td>Days of collection required, %</td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>76     (83.52)</td>
</tr>
<tr>
<td>2</td>
<td>13     (14.29)</td>
</tr>
<tr>
<td>3</td>
<td>2      (2.2)</td>
</tr>
<tr>
<td>Median CD34⁺ cells/kg 10⁶ collected (range)</td>
<td>33.73  (2.39-84.93)</td>
</tr>
<tr>
<td>Median days to neutrophil engraftment</td>
<td>11.30  (6-23)</td>
</tr>
<tr>
<td>Median days to platelet engraftment</td>
<td>13.92  (7-30)</td>
</tr>
</tbody>
</table>
control, as others have observed an antitumor effect in MM patients following the outpatient administration of VP-16 with G-CSF. The timing of collection with VP-16 and G-CSF also appeared to be very predictable, with most patients collecting on 1 day. In our study 76 patients (83.52%) of 91 patients stem cells were successfully collected after 1 mobilization. Finally, there was no obvious adverse consequence of exposure to VP-16 on ANC or PLT engraftment after subsequent autologous stem cell transplantation.

Our study group encompassed patients with various hematological malignancies. Most of the patients had received >2 lines treatment. The number of CD34+ cell yield in acute leukemia patients was relatively lower compared to patients with other disorders, which could not be statistically documented due to small numbers of the patients study group. An Italian retrospective study reported that acute myeloid leukemia patients had the highest incidence of poor mobilization among patients with hematologic malignancies. It is published that 10-30% of NHL patients were reported to be hard-to-mobilize or experienced a mobilization failure with standard protocols. On the other hand with a combination of CY and G-CSF, more than 95% of MM patients eligible for autologous stem cell transplantation could be successfully mobilized.

Our mobilization success was highly striking. On 76 patients (83.52%) stem cells were successfully collected after 1 mobilization. The median collected CD34+ cell number was 33.73×10^6 cells/kg. The high collected CD34+ cell number pickup the engraftment of neutrophil and PLT.

The side effects of mobilization chemotherapy were acceptable. Adverse effects of the regimen included supportive transfusions required in 59 patients (64.83%), and 30 patients (32.96%) with fever requiring hospitalization and intravenous antibiotics. Grade III or IV hematopoietic toxicity of chemotherapy had no significant effect on the mobilization efficacy. Supportive care and the incidence of febrile neutropenia were not significantly different from literature reported in CY plus G-CSF used mobilization regimen.

High failure rates can adversely affect patient outcomes, because these patients cannot proceed to transplantation without a repetition of mobilization and apheresis, which is associated with increased morbidity and resource utilization. Because of these reasons, advances in mobilization strategies are needed to improve patient outcomes. Novel agents used in conjunction with existing therapies have the potential to amplify CD34+ cell yields without introducing additional toxicity, thereby improving the process of PBSC mobilization in patients undergoing auto-HSCT for MM or NHL and HL.

The future of mobilization will use promising new agents in the context of a patient-tailored strategy that depends on individual disease characteristics and the nature of previous treatment.

**References**


